Loss of PTEN promotes resistance to T cell–mediated immunotherapy

Cancer Discovery

Volumn 6, Issue 2, 2016, Pages 202-216

  Peng, Weiyi ^a   Chen, Jie Qing ^a   Liu, Chengwen ^a   Malu, Shruti ^a   Creasy, Caitlin ^a   Tetzlaff, Michael T ^a   Xu, Chunyu ^a   McKenzie, Jodi A ^a   Zhang, Chunlei ^a   Liang, Xiaoxuan ^a   Williams, Leila J ^a   Deng, Wanleng ^a   Chen, Guo ^a   Mbofung, Rina ^a   Lazar, Alexander J ^a   Torres Cabala, Carlos A ^a   Cooper, Zachary A ^a   Chen, Pei Ling ^a   Tieu, Trang N ^a   Spranger, Stefani ^b   Yu, Xiaoxing ^a   Bernatchez, Chantale ^a   Forget, Marie Andree ^a   Haymaker, Cara ^a   Amaria, Rodabe ^a   McQuade, Jennifer L ^a   Glitza, Isabella C ^a   Cascone, Tina ^a   Li, Haiyan S ^a   Kwong, Lawrence N ^a   Heffernan, Timothy P ^a   Hu, Jianhua ^a   Bassett, Roland L ^a   Bosenberg, Marcus W ^c   Woodm An, Scott E ^a   Overwijk, Willem W ^a   Lizee, Gregory ^a   Roszik, Jason ^a   Gajewski, Thomas F ^b   Wargo, Jennifer A ^a   Gershenwald, Jeffrey E ^a   Radvanyi, Laszlo ^a   Davies, Michael A ^a   Hwu, Patrick ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; BETA CATENIN; BUPARLISIB; CASPASE 3; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NIVOLUMAB; PEMBROLIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B INHIBITOR; VASCULOTROPIN; AMINOPYRIDINE DERIVATIVE; ANTIBODY; CTLA4 PROTEIN, MOUSE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MORPHOLINE DERIVATIVE; NVP-BKM120; PDCD1 PROTEIN, MOUSE; PTEN PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MELANOMA; METASTATIC MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SERIAL ANALYSIS OF GENE EXPRESSION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; WESTERN BLOTTING; ANIMAL; DEFICIENCY; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; PROCEDURES; TUMOR CELL LINE;

AMINOPYRIDINES; ANIMALS; ANTIBODIES; CELL LINE, TUMOR; CTLA-4 ANTIGEN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMMUNOTHERAPY; MELANOMA; MICE; MORPHOLINES; PROGRAMMED CELL DEATH 1 RECEPTOR; PTEN PHOSPHOHYDROLASE; T-LYMPHOCYTES;

EID: 84957093642     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0283     Document Type: Article

References (49)

1. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521–32.
2. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23–34.
3. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012; 18: 6758–70.
4. Khalili JS, Liu S, Rodriguez-Cruz TG, Whittington M, Wardell S, Liu C, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012; 18: 5329–40.
5. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19: 1225–31.
6. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013; 19: 393–403.
7. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015; 523: 231–5.
8. Song MS, Salmena L, PandolfiPP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol 2012; 13: 283–96.
9. Aguissa-Toure AH, Li G. Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci 2012; 69: 1475–91.
10. Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 2012; 26: 1055–69.
11. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41: 544–52.
12. Bucheit AD, Chen G, Siroy AE, Tetzlaff M, Broaddus RR, Milton DR, et al. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res 2014; 20: 5527–36.
13. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, H utson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013; 31: 1767–74.
14. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 2010; 70: 8736–47.
15. Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA. Role and therapeutic potential of PI3K–mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 2012; 25: 248–58.
16. Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, et al. Impact of clinical and pathologic features on tumorinfiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 2011; 17: 4882–91.
17. Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012; 31: 446–57.
18. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160: 48–61.
19. Cancer Genome Atlas Network. Electronic address imo, Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma. Cell 2015; 161: 1681–96.
20. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13: 84–8.
21. Dong Y, Richards JA, Gupta R, Aung PP, Emley A, Kluger Y, et al. PTEN functions as a melanoma tumor suppressor by promoting host immune response. Oncogene 2014; 33: 4632–42.
22. Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014; 20: 3446–57.
23. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70: 6171–80.
24. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest 2013; 123: 1371–81.
25. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007; 39: 207–11.
26. Weersma RK, Zhernakova A, Nolte IM, Lefebvre C, Rioux JD, Mulder F, et al. ATG16L1 and IL23R are associated with infl ammatory bowel diseases but not with celiac disease in the Netherlands. Am J Gastroenterol 2008; 103: 621–7.
27. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008; 454: 776–9.
28. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008; 105: 7797–802.
29. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 2013; 19: 465–72.
30. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2014; 2: 643–54.
31. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105–16.
32. McDermott D, Lebbe C, Hodi FS, Maio M, Weber JS, Wolchok JD, et al. Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev 2014; 40: 1056–64.
33. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One 2013; 8: e65821.
34. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 2015; 112: 1501–9.
35. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359–71.
36. Voron T, Marcheteau E, Pernot S, Colussi O, Tartour E, Taieb J, et al. Control of the immune response by pro-angiogenic factors. Front Oncol 2014; 4: 70.
37. Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep 2014; 9: 75–89.
38. Thorburn A, Thamm DH, Gustafson DL. Autophagy and cancer therapy. Mol Pharmacol 2014; 85: 830–8.
39. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573–7.
40. Kim S, Ramakrishnan R, Lavilla-Alonso S, Chinnaiyan P, Rao N, Fowler E, et al. Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother 2014; 63: 1009–21.
41. Lorin S, Hamai A, Mehrpour M, Codogno P. Autophagy regulation and its role in cancer. Semin Cancer Biol 2013; 23: 361–79.
42. Arkenau H-T, Mateo J, Lemech CR, Infante JR, Burris HA, Bang Y-J, et al. A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. J Clin Oncol 32: 5s, 2014 (suppl; abstr 2514^).
43. Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, et al. Co-stimulation through 4–1BB/CD137 improves the expansion and function of CD8(+) melanoma tumorinfiltrating lymphocytes for adoptive T-cell therapy. PLoS One 2013; 8: e60031.
44. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 2010; 16: 5458–68.
45. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006; 126: 154–60.
46. Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014; 20: 2773–82.
47. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of infl ammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.
48. Benevolo M, Mottolese M, Tremante E, Rollo F, Diodoro MG, Ercolani C, et al. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J Transl Med 2011; 9: 184.
49. He L, Hakimi J, Salha D, Miron I, Dunn P, Radvanyi L. A sensitive fl ow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. J Immunol Methods 2005; 304: 43–59.